New Method Uses Simple Algebraic Equations to Enable Faster Processing of Large Volumes of COVID-19 Tests
|
By LabMedica International staff writers Posted on 09 Oct 2020 |

Illustration
A mathematician from Cardiff University has developed a new method for processing large volumes of COVID-19 tests which he believes could lead to significantly more tests being performed at once and results being returned much quicker.
Dr. Usama Kadri, from the Cardiff University’s School of Mathematics (Cardiff, UK), believes the new technique could allow many more patients to be tested using the same amount of tests tubes and with a lower possibility of false negatives occurring. Dr Kadri’s technique uses simple algebraic equations to identify positive samples in tests and takes advantage of a testing technique known as ‘pooling’. Pooling involves grouping a large number of samples from different patients into one test tube and performing a single test on that tube. If the tube is returned negative then you know that everybody from that group does not have the virus. Pooling can be applied by laboratories to test more samples in a shorter space of time, and works well when the overall infection rate in a certain population is expected to be low.
If a tube is returned positive then each person within that group needs to be tested once again, this time individually, to determine who has the virus. In this instance, and particularly when it is known that infection rates in the population are high, the savings from the pooling technique in terms of time and cost become less significant. However, Dr. Kadri’s new technique removes the need to perform a second round of tests once a batch is returned positive and can identify the individuals who have the virus using simple equations. The technique works with a fixed number of individuals and test tubes, for example 200 individuals and 10 test tubes, and starts by taking a fixed number of samples from a single individual, for example 5, and distributing these into 5 of the 10 test tubes.
Another 5 samples are taken from the second individual and these are distributed into a different combination of 5 of the 10 tubes. This is then repeated for each of the 200 individuals in the group so that no individual shares the same combination of tubes. Each of the 10 test tubes is then sent for testing and any tube that returns negative indicates that all patients that have samples in that tube must be negative. If only one individual has the virus, then the combinations of the tubes that return positive, which is unique to the individual, will directly indicate that individual. However, if the number of positive tubes is larger than the number of samples from each individual, in this example 5, then there should be at least two individuals with the virus. The individuals that have all of their test tubes return positive are then selected.
The method assumes that each individual that is positive should have the same quantity of virus in each tube, and that each of the individuals testing positive will have a unique quantity of virus in their sample which is different to the others. From this, the method then assumes that there are exactly two individuals with the virus and, for every two suspected individuals, a computer is used to calculate any combination of virus quantity that would return the actual overall quantity of virus that was measured in the tests. If the right combination is found then the selected two individuals have to be positive and no one else. Otherwise, the procedure is repeated but with an additional suspected individual, and so on until the right combination is found. So far, the method has been assessed using simulations of testing scenarios and Dr. Kadri acknowledges that lab testing will need to be carried out to increase confidence in the proposed method. Moreover, for clinical use, additional factors need to be considered including sample types, viral load, prevalence, and inhibitor substances.
“Applying the proposed method allows testing many more patients using the same number of testing tubes, where all positives are identified with no false negatives, and no need for a second round of independent testing, with the effective testing time reduced drastically,” Dr. Kadri said.
Related Links:
Cardiff University
Dr. Usama Kadri, from the Cardiff University’s School of Mathematics (Cardiff, UK), believes the new technique could allow many more patients to be tested using the same amount of tests tubes and with a lower possibility of false negatives occurring. Dr Kadri’s technique uses simple algebraic equations to identify positive samples in tests and takes advantage of a testing technique known as ‘pooling’. Pooling involves grouping a large number of samples from different patients into one test tube and performing a single test on that tube. If the tube is returned negative then you know that everybody from that group does not have the virus. Pooling can be applied by laboratories to test more samples in a shorter space of time, and works well when the overall infection rate in a certain population is expected to be low.
If a tube is returned positive then each person within that group needs to be tested once again, this time individually, to determine who has the virus. In this instance, and particularly when it is known that infection rates in the population are high, the savings from the pooling technique in terms of time and cost become less significant. However, Dr. Kadri’s new technique removes the need to perform a second round of tests once a batch is returned positive and can identify the individuals who have the virus using simple equations. The technique works with a fixed number of individuals and test tubes, for example 200 individuals and 10 test tubes, and starts by taking a fixed number of samples from a single individual, for example 5, and distributing these into 5 of the 10 test tubes.
Another 5 samples are taken from the second individual and these are distributed into a different combination of 5 of the 10 tubes. This is then repeated for each of the 200 individuals in the group so that no individual shares the same combination of tubes. Each of the 10 test tubes is then sent for testing and any tube that returns negative indicates that all patients that have samples in that tube must be negative. If only one individual has the virus, then the combinations of the tubes that return positive, which is unique to the individual, will directly indicate that individual. However, if the number of positive tubes is larger than the number of samples from each individual, in this example 5, then there should be at least two individuals with the virus. The individuals that have all of their test tubes return positive are then selected.
The method assumes that each individual that is positive should have the same quantity of virus in each tube, and that each of the individuals testing positive will have a unique quantity of virus in their sample which is different to the others. From this, the method then assumes that there are exactly two individuals with the virus and, for every two suspected individuals, a computer is used to calculate any combination of virus quantity that would return the actual overall quantity of virus that was measured in the tests. If the right combination is found then the selected two individuals have to be positive and no one else. Otherwise, the procedure is repeated but with an additional suspected individual, and so on until the right combination is found. So far, the method has been assessed using simulations of testing scenarios and Dr. Kadri acknowledges that lab testing will need to be carried out to increase confidence in the proposed method. Moreover, for clinical use, additional factors need to be considered including sample types, viral load, prevalence, and inhibitor substances.
“Applying the proposed method allows testing many more patients using the same number of testing tubes, where all positives are identified with no false negatives, and no need for a second round of independent testing, with the effective testing time reduced drastically,” Dr. Kadri said.
Related Links:
Cardiff University
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








